{"product_id":"thermofisher-pestle-analysis","title":"Thermo Fisher Scientific PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNavigate regulatory shifts, supply-chain pressures, and rapid biotech innovation with our PESTLE analysis tailored to Thermo Fisher Scientific—concise, current, and action-oriented to sharpen investment and strategy decisions. Purchase the full report for a deep-dive on political, economic, social, technological, legal, and environmental forces shaping the company and get ready-to-use insights for boardrooms and models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical tensions affecting supply chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing US-China trade frictions force Thermo Fisher to diversify suppliers and locations after 2023 tariffs raised component costs by an estimated 4–6%, with management citing supply-chain reconfiguration projects totaling roughly $400–600m through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment funding for life sciences research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant share of Thermo Fisher's revenue—about 40% of its 2024 sales—depends on academic and government research budgets, making it sensitive to political shifts in funding. Variations in NIH funding (FY2024 budget ~$48.4B) or ERC grants affect customer purchasing power and instrument procurement cycles. Sustained bipartisan support for biomedical innovation underpins long-term growth prospects in life sciences.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare policy and reimbursement reform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical debates on healthcare affordability and shifts toward value-based insurance models affect Thermo Fisher’s diagnostics and clinical trials, with US spending on healthcare reaching $4.6 trillion in 2023 (17.1% of GDP), pressuring payers to cut test reimbursements. Recent CMS proposals to revise Medicare Part B rates and 2024–25 state budget constraints risk lowering diagnostic reimbursements, which can defer hospital and biotech CAPEX—Thermo Fisher reported $2.5B capex guidance for 2024—forcing the company to realign products to cost-containment and outcome-based pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational security and pandemic preparedness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernments boosted biosecurity budgets after COVID-19; US BARDA funding rose to about $11.5B in 2024 for advanced preparedness, creating contracts for suppliers like Thermo Fisher to support stockpiling and surge capacity.\u003c\/p\u003e\n\u003cp\u003eThermo Fisher can leverage partnerships for rapid-response infrastructure; localized investments align with industrial policies—US CHIPS-style incentives and EU onshoring grants totaled tens of billions in 2023–25.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eIncreased government preparedness spending (eg BARDA $11.5B, 2024)\u003c\/li\u003e\n\u003cli\u003eOpportunities for supply-stockpiling contracts and rapid-response facilities\u003c\/li\u003e\n\u003cli\u003eAlignment with national onshoring incentives across US and EU\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory harmonization across international markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory harmonization shapes Thermo Fisher Scientifics market-entry; alignment on medical device and chemical safety standards across the US, EU and APAC can lower approval time and costs—global medical device market was $635B in 2024, emphasizing stakes for streamlined rules.\u003c\/p\u003e\n\u003cp\u003eActive participation in ICH, ISO and WHO forums lets Thermo Fisher push for unified approval pathways, potentially cutting administrative lag that affects time-to-revenue.\u003c\/p\u003e\n\u003cp\u003eDespite this, fragmentation in data privacy laws (e.g., 2024 GDPR enforcement actions up 15%) and divergent clinical trial protocols force localized compliance teams and increased legal spend—Thermo Fisher reported R\u0026amp;D and regulatory expenses of $3.1B in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHarmonization lowers approval costs and speeds entry into a $635B device market (2024)\u003c\/li\u003e\n\u003cli\u003eEngagement in ICH\/ISO\/WHO can streamline approvals and reduce administrative lag\u003c\/li\u003e\n\u003cli\u003eRising fragmentation in privacy and trial rules increases local compliance needs\u003c\/li\u003e\n\u003cli\u003eRegulatory spend pressure reflected in $3.1B R\u0026amp;D\/regulatory expense (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics, funding \u0026amp; regs reshape Thermo Fisher: supply chains, contracts, and costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical shifts—US-China trade tensions, NIH funding (~$48.4B FY2024), BARDA ($11.5B 2024), and healthcare cost debates—drive Thermo Fisher to diversify supply chains, pursue government contracts, and adapt pricing amid reimbursement pressures; regulatory harmonization (global device market $635B 2024) helps but data-privacy fragmentation raises compliance costs (R\u0026amp;D\/regulatory $3.1B FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH\u003c\/td\u003e\n\u003ctd\u003e$48.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBARDA\u003c\/td\u003e\n\u003ctd\u003e$11.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice market\u003c\/td\u003e\n\u003ctd\u003e$635B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/regulatory spend\u003c\/td\u003e\n\u003ctd\u003e$3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Thermo Fisher Scientific across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven trends and forward-looking insights to inform strategy, risk management, and investor communications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Thermo Fisher Scientific that can be dropped into presentations or shared across teams to quickly align on regulatory, technological, and market risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal interest rate environment and capital costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFluctuations in central bank policies—notably the Fed funds rate rising from ~0.25% in 2021 to 5.25–5.50% by end-2023 and remaining elevated through 2024—raise Thermo Fisher’s cost of debt, increasing WACC and making its acquisition-driven growth more expensive. Higher rates lift hurdle rates for new investments and compress deal valuations; deal activity in life sciences declined ~15% YoY in 2023. Elevated borrowing costs also strain biotech customers, reducing capital for R\u0026amp;D and purchases of high-end instruments, potentially pressuring Thermo Fisher’s equipment sales. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a multinational, Thermo Fisher's revenues are sensitive to USD moves versus the euro, yen and yuan; FX translational effects reduced reported revenue growth by an estimated 2.5 percentage points in FY2024, per company disclosures.\u003c\/p\u003e\n\u003cp\u003eForeign exchange headwinds can compress operating margins when strong dollar repatriates international sales; FY2024 currency effects lowered adjusted EPS by about $0.40. \u003c\/p\u003e\n\u003cp\u003eThe company uses dynamic hedging and natural offsets—forward contracts and fungible sourcing—but prolonged volatility, especially a 10% swing in major pairs in 2024, remains a material economic risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on raw materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePersistent inflation in energy, logistics and raw materials has pressured Thermo Fisher to adopt disciplined pricing; FY2025 guidance reflects input-cost headwinds after raw-material inflation averaged about 7–9% in 2024, forcing selective price increases to protect gross margin.\u003c\/p\u003e\n\u003cp\u003eThe company leverages scale—$44.4B revenue in FY2024—to negotiate supplier terms and mitigate inflation, but rapid spikes can cause short-term margin compression, as seen in Q4 2024 when gross margin dipped ~120 basis points year-over-year.\u003c\/p\u003e\n\u003cp\u003eManagement prioritizes balancing pass-through pricing with competitive positioning, targeting margin recovery while monitoring customer elasticity across life-science and clinical markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of emerging markets in Asia and Latin America\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic expansion in Asia and Latin America—GDP growth of 4.5% in Southeast Asia and 2.3% in Latin America in 2024—boosts lab build-outs and healthcare spending, enlarging markets for Thermo Fisher’s instruments, consumables and services.\u003c\/p\u003e\n\u003cp\u003eRising middle classes (an extra ~300 million consumers in Asia by 2025) increase demand for advanced diagnostics and pharmaceuticals, driving recurring consumables revenue and service contracts.\u003c\/p\u003e\n\u003cp\u003eThermo Fisher has increased regional investments, targeting double-digit CAGR markets to diversify away from North America and Europe and capture share in high-growth segments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAsia\/LatAm GDP growth 2024: ~4.5%\/2.3%\u003c\/li\u003e\n\u003cli\u003e~300M new middle-class consumers in Asia by 2025\u003c\/li\u003e\n\u003cli\u003eFocus on consumables, diagnostics, service contracts\u003c\/li\u003e\n\u003cli\u003eStrategic investments to achieve regional revenue diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotechnology sector funding and VC activity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe economic health of the early-stage biotech industry directly affects Thermo Fisher’s Life Sciences Solutions sales; global VC investment in biotech fell to about $34.5B in 2024 from $45B in 2021, tightening startup purchasing power.\u003c\/p\u003e\n\u003cp\u003eActive IPO and SPAC markets (biotech IPOs dropped ~40% in 2023–24) drive liquidity for lab equipment and CDMO spending; weaker markets delay orders and cut service demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 biotech VC: ~$34.5B\u003c\/li\u003e\n\u003cli\u003eBiotech IPOs down ~40% (2023–24)\u003c\/li\u003e\n\u003cli\u003eDirect impact: delayed orders, reduced CDMO demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacro Headwinds Cut Margins and Deals, Asian Growth Fuels Consumables Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher interest rates (Fed 5.25–5.50% end-2023, stayed elevated through 2024) raise Thermo Fisher’s WACC and borrowing costs, compressing deal activity (~15% decline in life-science M\u0026amp;A 2023) and pressuring equipment sales; FY2024 FX reduced revenue growth by ~2.5 pp and lowered adjusted EPS by ~$0.40; raw-material inflation (7–9% in 2024) trimmed gross margin ~120 bps in Q4 2024 while regional growth (SE Asia 4.5%, LatAm 2.3% in 2024) and ~300M new Asian middle-class consumers to 2025 support consumables and services.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue FY2024\u003c\/td\u003e\n\u003ctd\u003e$44.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX drag on rev growth\u003c\/td\u003e\n\u003ctd\u003e~2.5 pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj EPS FX impact\u003c\/td\u003e\n\u003ctd\u003e~$0.40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw-material inflation\u003c\/td\u003e\n\u003ctd\u003e7–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin Q4 2024\u003c\/td\u003e\n\u003ctd\u003e-120 bps YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech VC 2024\u003c\/td\u003e\n\u003ctd\u003e$34.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech IPO change\u003c\/td\u003e\n\u003ctd\u003e-~40% (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSE Asia GDP 2024\u003c\/td\u003e\n\u003ctd\u003e4.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatAm GDP 2024\u003c\/td\u003e\n\u003ctd\u003e2.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eThermo Fisher Scientific PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Thermo Fisher Scientific PESTLE analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning or investor review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751356477817,"sku":"thermofisher-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/thermofisher-pestle-analysis.png?v=1772230601","url":"https:\/\/growthsharematrix.com\/products\/thermofisher-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}